CCND1 and breast carcinoma: Several previous reports have shown that treatment of breast cancer cell lines with FGFR inhibitors downregulates CCND1 and CCND2 expression and inhibits CCND/CDK4 activity, resulting in decreased pRB phosphorylation [39,40].